These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35882361)

  • 1. Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors.
    Pedraza-Arevalo S; Alors-Pérez E; Blázquez-Encinas R; Herrera-Martínez AD; Jiménez-Vacas JM; Fuentes-Fayos AC; Reyes Ó; Ventura S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Gálvez-Moreno MA; Gahete MD; Ibáñez-Costa A; Luque RM; Castaño JP
    Transl Res; 2023 Jan; 251():63-73. PubMed ID: 35882361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery.
    Blázquez-Encinas R; García-Vioque V; Caro-Cuenca T; Moreno-Montilla MT; Mangili F; Alors-Pérez E; Ventura S; Herrera-Martínez AD; Moreno-Casado P; Calzado MA; Salvatierra Á; Gálvez-Moreno MA; Fernandez-Cuesta L; Foll M; Luque RM; Alcala N; Pedraza-Arevalo S; Ibáñez-Costa A; Castaño JP
    J Transl Med; 2023 Dec; 21(1):879. PubMed ID: 38049848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response.
    Alors-Pérez E; Pedraza-Arevalo S; Blázquez-Encinas R; García-Vioque V; Agraz-Doblas A; Yubero-Serrano EM; Sánchez-Frías ME; Serrano-Blanch R; Gálvez-Moreno MÁ; Gracia-Navarro F; Gahete MD; Arjona-Sánchez Á; Luque RM; Ibáñez-Costa A; Castaño JP
    Mol Ther Nucleic Acids; 2024 Mar; 35(1):102090. PubMed ID: 38187140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters.
    Luque RM; Sampedro-Nuñez M; Gahete MD; Ramos-Levi A; Ibáñez-Costa A; Rivero-Cortés E; Serrano-Somavilla A; Adrados M; Culler MD; Castaño JP; Marazuela M
    Oncotarget; 2015 Aug; 6(23):19619-33. PubMed ID: 26124083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nova1 is a master regulator of alternative splicing in pancreatic beta cells.
    Villate O; Turatsinze JV; Mascali LG; Grieco FA; Nogueira TC; Cunha DA; Nardelli TR; Sammeth M; Salunkhe VA; Esguerra JL; Eliasson L; Marselli L; Marchetti P; Eizirik DL
    Nucleic Acids Res; 2014 Oct; 42(18):11818-30. PubMed ID: 25249621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOVA1 promotes NSCLC proliferation and invasion by activating Wnt/β-catenin signaling.
    Qu L; Tian Y; Wang F; Li Z
    BMC Cancer; 2022 Oct; 22(1):1091. PubMed ID: 36284263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
    Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
    Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets.
    Alors-Pérez E; Blázquez-Encinas R; Moreno-Montilla MT; García-Vioque V; Jiménez-Vacas JM; Mafficini A; González-Borja I; Luchini C; Sánchez-Hidalgo JM; Sánchez-Frías ME; Pedraza-Arevalo S; Romero-Ruiz A; Lawlor RT; Viúdez A; Gahete MD; Scarpa A; Arjona-Sánchez Á; Luque RM; Ibáñez-Costa A; Castaño JP
    Mol Oncol; 2024 May; ():. PubMed ID: 38790138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis.
    Krach F; Wheeler EC; Regensburger M; Boerstler T; Wend H; Vu AQ; Wang R; Reischl S; Boldt K; Batra R; Aigner S; Ravits J; Winkler J; Yeo GW; Winner B
    Acta Neuropathol; 2022 Sep; 144(3):413-435. PubMed ID: 35778567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOVA1 directs PTBP1 to hTERT pre-mRNA and promotes telomerase activity in cancer cells.
    Sayed ME; Yuan L; Robin JD; Tedone E; Batten K; Dahlson N; Wright WE; Shay JW; Ludlow AT
    Oncogene; 2019 Apr; 38(16):2937-2952. PubMed ID: 30568224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Venegas-Moreno E; Rivero-Cortés E; Dios E; Moreno-Moreno P; Madrazo-Atutxa A; Remón P; Solivera J; Wildemberg LE; Kasuki L; López-Fernández JM; Gadelha MR; Gálvez-Moreno MA; Soto-Moreno A; Gahete MD; Castaño JP; Luque RM
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST
    Pedraza-Arevalo S; Ibáñez-Costa A; Blázquez-Encinas R; Branco MR; Vázquez-Borrego MC; Herrera-Martínez AD; Venegas-Moreno E; Serrano-Blanch R; Arjona-Sánchez Á; Gálvez-Moreno MA; Korbonits M; Soto-Moreno A; Gahete MD; Charalambous M; Luque RM; Castaño JP
    Mol Oncol; 2022 Feb; 16(3):764-779. PubMed ID: 34601790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transcriptional regulation of neuro-oncological ventral antigen 1 by the neuronal RNA-binding proteins ELAV.
    Ratti A; Fallini C; Colombrita C; Pascale A; Laforenza U; Quattrone A; Silani V
    J Biol Chem; 2008 Mar; 283(12):7531-41. PubMed ID: 18218628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
    Marini F; Giusti F; Brandi ML
    Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic NOVA1 expression dysregulates alternative splicing in breast cancer.
    Moakley DF; Zhang C
    bioRxiv; 2024 Jul; ():. PubMed ID: 39026722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features.
    Konukiewitz B; von Hornstein M; Jesinghaus M; Steiger K; Weichert W; Detlefsen S; Kasajima A; Klöppel G
    Hum Pathol; 2020 Aug; 102():79-87. PubMed ID: 32668277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential.
    Alors-Pérez E; Pedraza-Arevalo S; Blázquez-Encinas R; Moreno-Montilla MT; García-Vioque V; Berbel I; Luque RM; Sainz B; Ibáñez-Costa A; Castaño JP
    J Exp Clin Cancer Res; 2023 Oct; 42(1):282. PubMed ID: 37880792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.